Back to Search
Start Over
Targeting EGFR in Combination with Nutritional Supplements on Antitumor Efficacy in a Lung Cancer Mouse Model.
- Source :
-
Marine drugs [Mar Drugs] 2022 Nov 29; Vol. 20 (12). Date of Electronic Publication: 2022 Nov 29. - Publication Year :
- 2022
-
Abstract
- Selenium (Se) and fish oil (FO) exert anti-epidermal growth factor receptor (EGFR) action on tumors. This study aimed to compare the anti-cancer efficacy of EGFR inhibitors (gefitinib and erlotinib) alone and in combination with nutritional supplements of Se/FO in treating lung cancer. Lewis LLC1 tumor-bearing mice were treated with a vehicle or Se/FO, gefitinib or gefitinib plus Se/FO, and erlotinib or erlotinib plus Se/FO. The tumors were assessed for mRNA and protein expressions of relevant signaling molecules. Untreated tumor-bearing mice had the lowest body weight and highest tumor weight and volume of all the mice. Mice receiving the combination treatment with Se/FO and gefitinib or erlotinib had a lower tumor volume and weight and fewer metastases than did those treated with gefitinib or erlotinib alone. The combination treatment exhibited greater alterations in receptor signaling molecules (lower EGFR/TGF-β/TβR/AXL/Wnt3a/Wnt5a/FZD7/β-catenin; higher GSK-3β) and immune checkpoint molecules (lower PD-1/PD-L1/CD80/CTLA-4/IL-6; higher NKp46/CD16/CD28/IL-2). These mouse tumors also had lower angiogenesis, cancer stemness, epithelial to mesenchymal transitions, metastases, and proliferation of Ki-67, as well as higher cell cycle arrest and apoptosis. These preliminary results showed the Se/FO treatment enhanced the therapeutic efficacies of gefitinib and erlotinib via modulating multiple signaling pathways in an LLC1-bearing mouse model.
- Subjects :
- Animals
Mice
Glycogen Synthase Kinase 3 beta metabolism
Carcinoma, Lewis Lung drug therapy
Dietary Supplements
ErbB Receptors antagonists & inhibitors
Erlotinib Hydrochloride pharmacology
Erlotinib Hydrochloride therapeutic use
Fish Oils therapeutic use
Gefitinib pharmacology
Gefitinib therapeutic use
Protein Kinase Inhibitors pharmacology
Protein Kinase Inhibitors therapeutic use
Selenium therapeutic use
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1660-3397
- Volume :
- 20
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Marine drugs
- Publication Type :
- Academic Journal
- Accession number :
- 36547898
- Full Text :
- https://doi.org/10.3390/md20120751